Mantle Irradiation for Hodgkin's Disease

Status Completed

Clinical Trial Summary

The purpose of this study it to evaluate the effectiveness of radiation therapy limited to above the diaphragm in patients with pathological stage IA-IIA Hodgkin's disease.

Clinical Trial Description

- Eligble patients will receive a course of radiation therapy directed to above the diaphragm only.

- Patients would have bloodwork and chest x-rays performed 4 times per year for the first two years, 3 times per year for the third year, and 2 times per year for the fourth and fifth years. After five years, yearly check-ups are performed.

- In addition to the above follow-up, patients will receive, once or twice a year for the first 5 years, an abdominal-pelvic CT scan and/or gallium scan. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00165269
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	May 1992
Completion date	February 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01665768` - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma	Phase 2
Completed	`NCT01188798` - Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies	Phase 3
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00150462` - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies	Phase 1
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Completed	`NCT02856646` - Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Completed	`NCT01458288` - A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease	Phase 2
Completed	`NCT00990587` - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy	Phase 1
Completed	`NCT00469729` - Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy	Phase 2/Phase 3
Terminated	`NCT00594308` - In-Vivo Activated T-Cell Depletion to Prevent GVHD	N/A
Completed	`NCT00552825` - Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children	N/A
Completed	`NCT00165438` - Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy	N/A
Terminated	`NCT00176930` - Stem Cell Transplant for Hematological Malignancy	N/A
Recruiting	`NCT02007811` - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination	Phase 1/Phase 2
Completed	`NCT01221857` - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT00569842` - Investigation of the Cylex® ImmuKnow® Assay	N/A
Completed	`NCT00665314` - Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).	Phase 2
Completed	`NCT00284804` - A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease	Phase 2
Completed	`NCT00256191` - Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies	Phase 1
Completed	`NCT00396201` - AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease	Phase 2